Cause of mortality and sarcopenia in patients with idiopathic pulmonary fibrosis receiving antifibrotic therapy
Y Suzuki, Y Aono, M Kono, H Hasegawa… - …, 2021 - Wiley Online Library
… sarcopenia is its involvement in the pathogenesis of disease progression as well as in
therapeutic … , emerging evidence has confirmed that antifibrotic therapy (AFT) reduces the risks of …
therapeutic … , emerging evidence has confirmed that antifibrotic therapy (AFT) reduces the risks of …
Sarcopenia in idiopathic pulmonary fibrosis: a prospective study exploring prevalence, associated factors and diagnostic approach
P Faverio, A Fumagalli, S Conti, F Madotto, F Bini… - Respiratory …, 2022 - Springer
… of probable sarcopenia was 19.6% (10 cases). No differences in regards to antifibrotic treatment
… side effects were observed between patients with and without sarcopenia at follow-up. …
… side effects were observed between patients with and without sarcopenia at follow-up. …
Frequency and impact on clinical outcomes of sarcopenia in patients with idiopathic pulmonary fibrosis
K Fujita, H Ohkubo, A Nakano, Y Mori… - Chronic Respiratory …, 2022 - journals.sagepub.com
… On the other hand, there were no significant differences in comorbidities or treatments (antifibrotic
drugs or corticosteroids) between the groups. Similarly, there were no significant …
drugs or corticosteroids) between the groups. Similarly, there were no significant …
Sarcopenia contributes to the progression of nonalcoholic fatty liver disease-related fibrosis: a meta-analysis
X Pan, Y Han, T Zou, G Zhu, K Xu, J Zheng… - Digestive …, 2018 - karger.com
… Our results found that sarcopenia patients had a 1.3-fold statistical increase of developing
… when compared with subjects without sarcopenia. The above-mentioned association was …
… when compared with subjects without sarcopenia. The above-mentioned association was …
Geriatric Nutritional Risk Index is a predictor of tolerability of antifibrotic therapy and mortality risk in patients with idiopathic pulmonary fibrosis
Y Mochizuka, Y Suzuki, M Kono, H Hasegawa… - …, 2023 - Wiley Online Library
… of sarcopenia and cachexia, which are often found in patients … mortality in patients with
IPF receiving antifibrotic therapy. … were found to increase with lower BMI in patients with IPF. …
IPF receiving antifibrotic therapy. … were found to increase with lower BMI in patients with IPF. …
Prevalence and risk factors of sarcopenia in idiopathic pulmonary fibrosis: a systematic review and meta-analysis
J Li, Y Lu, M Deng, R Tong, Q Zhang, Y Bian… - Frontiers in …, 2023 - frontiersin.org
… antifibrotic therapy, some patients with IPF may live longer (11, 12). Considering the adverse
outcomes that sarcopenia can cause in patients … awareness of sarcopenia as a comorbidity. …
outcomes that sarcopenia can cause in patients … awareness of sarcopenia as a comorbidity. …
Impact of sarcopenia defined by carina-level skeletal muscle mass on the long-term prognosis of patients with idiopathic pulmonary fibrosis
… oxygen therapy, and medications (steroids and antifibrotic drugs) were collected from the
electronic medical records. The medications included not only the drugs for the treatment of IPF…
electronic medical records. The medications included not only the drugs for the treatment of IPF…
Dynapenia is highly prevalent in older patients with advanced idiopathic pulmonary fibrosis
M Bocchino, P Alicante, L Capitelli, AA Stanziola… - Scientific Reports, 2021 - nature.com
… decline independently of BMI and had a greater effect in patients with > 5% weight loss 8 . In
… IPF patients under anti-fibrotic therapy had skeletal muscle loss and that sarcopenia was a …
… IPF patients under anti-fibrotic therapy had skeletal muscle loss and that sarcopenia was a …
Uremic sarcopenia: clinical evidence and basic experimental approach
H Nishi, K Takemura, T Higashihara, R Inagi - Nutrients, 2020 - mdpi.com
… , it has been reported that sarcopenia obesity is not a risk for mortality in CKD patients [24].
In … the general population and CKD patients, and the study may include sarcopenia obesity. …
In … the general population and CKD patients, and the study may include sarcopenia obesity. …
Frequency and Clinical Relevance of Sarcopenia in Patients with Idiopathic Pulmonary Fibrosis
H Ohkubo, K Fujita, A Nakano, N Takeda, K Fukumitsu… - papers.ssrn.com
… In the comparison of PROs between the sarcopenic and non-sarcopenic patients with 5 …
and sarcopenia in patients with idiopathic 14 pulmonary fibrosis receiving antifibrotic therapy, …
and sarcopenia in patients with idiopathic 14 pulmonary fibrosis receiving antifibrotic therapy, …
相关搜索
- idiopathic pulmonary fibrosis sarcopenia in patients
- insights ipf antifibrotic treatment in patients
- clinically significant entity sarcopenia in patients
- sarcopenia and frailty in patients
- surrogate marker sarcopenia in patients
- lung function antifibrotic treatment in patients
- survival in patients antifibrotic therapy
- cause of mortality antifibrotic therapy
- mortality risk in patients antifibrotic therapy
- frequency and impact sarcopenia in patients
- geriatric nutritional risk index antifibrotic therapy
- antifibrotic treatment presence or absence
- clinical relevance sarcopenia in patients
- clinical outcomes sarcopenia in patients
- fatty liver disease sarcopenia in patients
- patients with outcomes relationship of sarcopenia